Literature DB >> 15834064

Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy.

D Wendling, B Auge, D Bettinger, A Lohse, G Le Huede, S Bresson-Hadni, E Toussirot, J-P Miguet, G Herbein, V Di Martino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15834064      PMCID： PMC1755487          DOI： 10.1136/ard.2004.031187

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  21 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

2.  Restoration of Wnt/β-catenin signaling attenuates alcoholic liver disease progression in a rat model.

Authors:  Chiung-Kuei Huang; Tunan Yu; Suzanne M de la Monte; Jack R Wands; Zoltan Derdak; Miran Kim
Journal:  J Hepatol       Date:  2015-02-24       Impact factor: 25.083

3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 4.  Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.

Authors:  L H Calabrese; N N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2006-04-20       Impact factor: 19.103

5.  A practical approach to monitoring patients on biological agents for the treatment of psoriasis.

Authors:  Jason J Emer; Amylynne Frankel; Joshua A Zeichner
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

Review 6.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 7.  Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.

Authors:  Pilar López-Serrano; Elsa de la Fuente Briongos; Elisa Carrera Alonso; Jose Lázaro Pérez-Calle; Conrado Fernández Rodríguez
Journal:  World J Hepatol       Date:  2015-03-27

8.  Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-06-14       Impact factor: 6.047

9.  Prevalence of hepatitis B and C infections in rheumatoid arthritis and ankylosing spondylitis: A multicenter countrywide study.

Authors:  Neslihan Yılmaz; Ömer Karadağ; Gezmiş Kimyon; Ayten Yazıcı; Sema Yılmaz; Umut Kalyoncu; Timuçin Kaşifoğlu; Hakan Temiz; Birol Baysal; Nurdan Tözün
Journal:  Eur J Rheumatol       Date:  2014-06-01

10.  Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab.

Authors:  Keisuke Ojiro; Makoto Naganuma; Hirotoshi Ebinuma; Hiroyoshi Kunimoto; Shinichiro Tada; Haruhiko Ogata; Yasushi Iwao; Hidetsugu Saito; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2008-07-01       Impact factor: 7.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.